Show simple item record

dc.creatorLakić, Dragana
dc.creatorPetrova, Guenka
dc.creatorBogavac-Stanojević, Nataša
dc.creatorJelić-Ivanović, Zorana
dc.date.accessioned2019-09-02T11:23:35Z
dc.date.available2019-09-02T11:23:35Z
dc.date.issued2011
dc.identifier.issn1310-2818
dc.identifier.urihttp://farfar.pharmacy.bg.ac.rs/handle/123456789/1480
dc.description.abstractDiscounting adjusts future costs and benefits in terms of their present value. The purpose of this study was to present the effect of discounting on Markov model prepared for the evaluation of the different antihypertensive treatments in Serbia. The Markov model consisting of eight states with the cycle length of six months was constructed. Comparator strategies were diuretic, beta blocker; calcium channel blocker and ACE inhibitors. All therapeutic strategies were compared with strategy no intervention". Complications of hypertension (acute myocardial infraction, angina pectoris or stroke alone or in combinations) and total mortality were observed as outcomes. Time horizon of the study was lifetime of the patient or 100 years old, due to assumption that 99% of the cohort would die at that age. Analyses were performed from the third-party payer perspective. Annual discount rate of 5% was applied at all future costs and effects. Undiscounted results showed that patients who started treatment with a beta blocker had the highest life expectancy (49.00 QALY) and being the most cost-effective strategy (ICER = (sic)46.63/QALY compared to no intervention). In the case of discounting the highest gain in the QALY had patients who were on beta blocker, 23.7 QALY. After the discounting cost-effective strategies were ACE inhibitor (ICER = (sic)253.08/QALY compared to no intervention) and diuretic (ICER = (sic)262.54/QALY compared to no intervention). The results of the study showed that the discounting could change the choice of cost-effective therapeutic strategy Biotechnol. & Biotechnol. Eq. 2011, 25(3), 2555-2558en
dc.publisherTaylor & Francis Ltd, Abingdon
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175035/RS//
dc.rightsopenAccess
dc.sourceBiotechnology & Biotechnological Equipment
dc.subjectMarkov modelen
dc.subjectdiscountingen
dc.subjectantihypertensive medicationen
dc.titleImpact of discounting in pharmacoeconomic modeling. A case studyen
dc.typearticle
dc.rights.licenseBY-NC
dcterms.abstractЛакић, Драгана; Богавац-Станојевић, Наташа; Јелић-Ивановић, Зорана; Петрова, Гуенка;
dc.citation.volume25
dc.citation.issue3
dc.citation.spage2555
dc.citation.epage2558
dc.citation.other25(3): 2555-2558
dc.citation.rankM23
dc.identifier.wos000294146000023
dc.identifier.doi10.5504/BBEQ.2011.0065
dc.identifier.scopus2-s2.0-80053064130
dc.identifier.fulltexthttp://farfar.pharmacy.bg.ac.rs//bitstream/id/360/1478.pdf
dc.identifier.rcubconv_2502
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record